IllinoisVENTURES is committed to helping entrepreneurs and technical founders to build world-changing businesses with the potential to create new market opportunities or significantly expand existing ones. During the course of the past six years we have led or collaborated on the initial funding of over 40 new ventures spanning a broad spectrum of scientific and technological innovation across multiple domains.
-
Catylix, Inc. is working to develop better methods for producing biologically-active compounds with improved pharmacokinetic properties for medicinal, veterinary and agrochemical applications.
-
Cell Habitats, Inc. is redefining the field of tissue regeneration by harnessing the body's own endogenous stem cells to restore normal function to damaged or diseased tissue.
-
Common Ground is committed to building new kinds of knowledge communities, innovative in their media and their messages.
-
Conkwest is an innovative life sciences company that is developing and commercializing a robust product pipeline for the treatment of cancers and viral infections.
-
eMotion Corporation, Inc. aims to emotionally connect people by a product which facilitates wireless-based human-to-human interaction.
-
PharmaIN is a development stage biopharmaceutical company focused on enabling and improving injectable therapeutics based on the Protected Graft Copolymer (PGC™), its patented and proprietary drug delivery technology licensed from Massachusetts General Hospital. PharmaIN is focused on half-life extension and targeted delivery of proteins, peptides, siRNA, and potent small molecule therapeutics.
-
PrintEco produces software which reduces wasted space when printing documents and web pages, saving a firm printing costs and reducing its environmental footprint.
-
PVPower is a distributor of solar panels, auxiliary technology, and design systems for solar power implementation.
-
Next Big Sound provides a centralized place to monitor all the behavior and activity happening for musical artists both online and off, thus determining their popularity.
-
ToleroGenics, Inc. is focused on developing novel pharmaceutical approaches to treating autoimmune diseases.
-
Vanquish Oncology, Inc. is a drug development company focused on targeting molecular defects in specific cancer cells to create personalized oncology therapeutics for unmet or underserved cancer markets.









